Immunoinformatics-driven multi-epitope vaccine design targeting PSMA, STEAP1, and B7H3 for prostate cancer


Creative Commons License

Runtunuwu S. V. B. E., Tallei T. E., Kim H. J., Park M. N., ÇELİK İ., KIRILMAZ B., ...Daha Fazla

FRONTIERS IN MEDICINE, cilt.13, 2026 (SCI-Expanded, Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 13
  • Basım Tarihi: 2026
  • Doi Numarası: 10.3389/fmed.2026.1716345
  • Dergi Adı: FRONTIERS IN MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, Directory of Open Access Journals
  • Erciyes Üniversitesi Adresli: Evet

Özet

Introduction Prostate cancer remains a major global health challenge, necessitating precision immunotherapeutic strategies tailored to tumor-associated antigens. This study aimed to design a multi-epitope peptide vaccine targeting prostate-specific membrane antigen (PSMA), six-transmembrane epithelial antigen of prostate 1 (STEAP1), and B7-H3, three biomarkers strongly associated with prostate cancer progression.Methods A multi-layered immunoinformatics-driven approach was employed, integrating epitope prediction, antigenicity and immunogenicity assessment, allergenicity and toxicity screening, population coverage analysis, molecular docking, and molecular dynamics simulations. Selected epitopes were assembled into a vaccine construct using appropriate adjuvants and linkers to enhance immune activation and structural stability.Results The designed vaccine construct demonstrated extensive global HLA allele coverage (97.51%), strong binding affinity to B-cell receptors, MHC molecules, and favorable structural stability during molecular dynamics simulations.Discussion These findings suggest that the proposed multi-epitope vaccine represents a promising immunotherapeutic candidate for prostate cancer and warrants further experimental validation.